Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Breast Neoplasms 3Neoplasm Metastasis 2Leukemia, B-Cell 2Urinary Bladder Neoplasms 1Polycystic Ovary Syndrome 1Parathyroid Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Hyperparathyroidism, Primary 1Head and Neck Neoplasms 1Diabetes Mellitus 1Carcinoma, Renal Cell 1Carcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 18Cisplatin 12Oxaliplatin 7pembrolizumab 6Nivolumab 6Capecitabine 4trametinib 3Fluorouracil 3Bevacizumab 3tremelimumab 2lenvatinib 2durvalumab 2derazantinib 2atezolizumab 2Trastuzumab 2Ramucirumab 2Radiofrequency Ablation 2Panitumumab 2Leucovorin 2Cryosurgery 2zanidatamab 1vandetanib 1tucatinib 1tocilizumab 1telotristat ethyl 1sargramostim 1rucaparib 1regorafenib 1pertuzumab 1milademetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Biliary Tract Neoplasms × Tablets × Clear all
NCT01943864 2017-05-31

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

GlaxoSmithKline

Phase 2 Completed
20 enrolled 27 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡